In conclusion, we demonstrated that budesonide ameliorates lung injury and suppresses uncontrolled inflammation via inhibition of the NLRP3 inflammasome in LPS-induced ALI, indicating that budesonide inhalation may be an effective therapy for ARDS in clinical practice. The gene discussed is NLRP3; the disease is acute respiratory distress syndrome.